Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); For A Few Pennies More, WPI Takes Big Time Price Increases
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Watson Pharmaceuticals (NYSE: WPI).
Analyst, Elliot Wilbur, said, "Generic leaders are supposed to consolidate market share and, if possible, raise price when afforded the rare opportunity to do so, and that is exactly what WPI has done on its market-leading hydrocodone/APAP line of products. Though this product line has diminished in relative importance to WPI over the years with annualized sales just north of $200.0MM, the price increases add some decent incremental EPS power given WPI’s declining tax rate and low share base."
"Upside risk to our stance on WPI would be a greater than expected decline in tax rate paid by WPI, while risk to the downside could result from moving hydrocodone products to Schedule II classification."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $72.20 yesterday.
Analyst, Elliot Wilbur, said, "Generic leaders are supposed to consolidate market share and, if possible, raise price when afforded the rare opportunity to do so, and that is exactly what WPI has done on its market-leading hydrocodone/APAP line of products. Though this product line has diminished in relative importance to WPI over the years with annualized sales just north of $200.0MM, the price increases add some decent incremental EPS power given WPI’s declining tax rate and low share base."
"Upside risk to our stance on WPI would be a greater than expected decline in tax rate paid by WPI, while risk to the downside could result from moving hydrocodone products to Schedule II classification."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $72.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Needham Reiterates Buy Rating on Harmonic Inc. (HLIT)
- Nu Holdings (Nubank) (NU) PT Raised to $19 at Needham
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
